ArticleNature communications2023
Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.Blood advances · 2026Article
- Serum metabolomics signatures after an acute bout of combined traditional or high-intensity tactical training in young adults.Physiological reports · 2026Article
- Genomic context of mutations in MIR142 in blood cancers: summary and integrative analysis.Cellular & molecular biology letters · 2026Review
- Loss of endothelial miR-126 drives age-related decline in hematopoiesis.Haematologica · 2026Article
- Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities.Cancers · 2026Review
- FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Cell reports. Medicine · 2026Article
- Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy.Nature communications · 2026Article
- MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia.Journal of hematology & oncology · 2025Article
- Elevated Microbially-Derived Metabolites in Autism: A Possible Diagnostic Screening Test for a Distinct ASD Phenotype.Research square · 2025Article
- Exercise-regulated lipolysis: Its role and mechanism in health and diseases.Journal of advanced research · 2025Review
- The roles of non-coding RNAs (ncRNAs) in the function of leukemic stem cells (LSCs): a comprehensive review.Discover oncology · 2025Review
- Role of MicroRNAs in Acute Myeloid Leukemia.Genes · 2025Review
- PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.Nature communications · 2025Article
- Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.Molecular cancer · 2024Article
- Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development.Cancer research · 2024Article
- State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.Leukemia · 2024Article
- State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia.bioRxiv : the preprint server for biology · 2023Article
- CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML.Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 3 countries.
Bin Zhang *Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA. bzhang@coh.org.ORCID http://orcid.org/0000-0003-4703-7524
Dandan Zhao *Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.
Fang Chen *Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.
David FrankhouserDepartment of Computational and Quantitative Medicine, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-8233-5853
Huafeng WangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.
Khyatiben V PathakCancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Lei DongDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Anakaren TorresCancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Krystine Garcia-MansfieldCancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0002-9089-2254
Yi ZhangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.
Dinh Hoa HoangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.
Min-Hsuan ChenCity of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute, Duarte, CA, USA.
Shu TaoCity of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-5177-6771
Hyejin ChoCity of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-9954-8118
Yong LiangDNA/RNA Peptide Shared Resources, Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-7225-7062
Danilo PerrottiDepartment of Medicine and Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine Baltimore, Baltimore, MD, USA.
Sergio BranciamoreDepartment of Computational and Quantitative Medicine, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.
Russell RockneDepartment of Computational and Quantitative Medicine, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-1557-159X
Xiwei WuCity of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute, Duarte, CA, USA.
Lucy GhodaDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.
Ling LiDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-7568-939X
Jie JinDepartment of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, PR China.
Jianjun ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, USA.ORCID http://orcid.org/0000-0003-3749-2902
Jianhua YuDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-0326-3223
Michael A CaligiuriDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-4095-3020
Ya-Huei KuoDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-2595-0419
Mark BoldinDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Rui SuDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, USA.ORCID http://orcid.org/0000-0002-4807-6229
Piotr SwiderskiDNA/RNA Peptide Shared Resources, Beckman Research Institute, Duarte, CA, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-6003-1816
Patrick PirrotteCancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0003-1360-6039
Le Xuan Truong NguyenDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA. lenguyen@coh.org.
Guido MarcucciDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA, USA. gmarcucci@coh.org.ORCID http://orcid.org/0000-0002-3983-5908
City of Hope · USCity Of Hope National Medical Center · USTranslational Genomics Research Institute · USBeckman Research InstituteUniversity of Maryland, Baltimore · USZhejiang University · CN
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3MTargeting MicroRNAs to Eradicate Leukemia Stem CellsR01CA205247 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI KUO, YA-HUEI, MARCUCCI, GUIDO · 2017 to 2025
$4.8MThe role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemiaR01CA271497 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Jianjun Chen · 2022 to 2026
$2.8MTargeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MTET2-mediated epitranscriptomic regulation in leukemia microenvironmentR01CA280389 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Jianjun Chen · 2023 to 2026
$2.7MThe Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AMLR01CA258981 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GUIDO MARCUCCI, BIN ZHANG · 2022 to 2026
$2.7MVascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?R01CA248475 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MARCUCCI, GUIDO, ZHANG, BIN · 2020 to 2024
$2.5MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MThe role of miR-142 in regulatory T cell Development and functionR01AI146313 · NIAID · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BOLDIN, MARK P · 2020 to 2024
$2.2MNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA205247NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NCI NIH HHS R01 CA248475NCI NIH HHS R01 CA258981NCI NIH HHS R01 CA271497NCI NIH HHS R01 CA280389NIAID NIH HHS R01 AI146313
Abstract
The mechanisms underlying the transformation of chronic myeloid leukemia (CML) from chronic phase (CP) to blast crisis (BC) are not fully elucidated. Here, we show lower levels of miR-142 in CD34
Indexed as
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidLeukemia, Myeloid, Chronic-PhaseMicroRNAsAnimalsBlast CrisisHumansMiceStem CellsMicroRNAsMIRN142 microRNA, humanMirn142 microRNA, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.